The p140Cap adaptor protein as a molecular hub to block cancer aggressiveness.
Adaptor Proteins, Signal Transducing
/ genetics
Adaptor Proteins, Vesicular Transport
/ genetics
Animals
Breast Neoplasms
/ genetics
Carcinogenesis
/ genetics
Female
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Mice
Neoplasm Metastasis
Neuroblastoma
/ genetics
Receptor, ErbB-2
/ genetics
Signal Transduction
/ genetics
Chromosome 17q12
Gene amplification
Interactome analysis
Metastasis
SRCIN1
miRNA
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
18
05
2020
accepted:
05
10
2020
revised:
03
09
2020
pubmed:
21
10
2020
medline:
4
3
2021
entrez:
20
10
2020
Statut:
ppublish
Résumé
The p140Cap adaptor protein is a scaffold molecule encoded by the SRCIN1 gene, which is physiologically expressed in several epithelial tissues and in the neurons. However, p140Cap is also strongly expressed in a significant subset of cancers including breast cancer and neuroblastoma. Notably, cancer patients with high p140Cap expression in their primary tumors have a lower probability of developing a distant event and ERBB2-positive breast cancer sufferers show better survival. In neuroblastoma patients, SRCIN1 mRNA levels represent an independent risk factor, which is inversely correlated to disease aggressiveness. Consistent with clinical data, SRCIN1 gain or loss of function mouse models demonstrated that p140Cap may affect tumor growth and metastasis formation by controlling the signaling pathways involved in tumorigenesis and metastatic features. This study reviews data showing the relevance of SRCIN1/p140Cap in cancer patients, the impact of SRCIN1 status on p140Cap expression, the specific mechanisms through which p140Cap can limit cancer progression, the molecular functions regulated by p140Cap, along with the p140Cap interactome, to unveil its key role for patient stratification in clinics.
Identifiants
pubmed: 33079227
doi: 10.1007/s00018-020-03666-w
pii: 10.1007/s00018-020-03666-w
pmc: PMC7904710
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Adaptor Proteins, Vesicular Transport
0
SRCIN1 protein, human
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1355-1367Subventions
Organisme : Associazione Italiana Ricerca cancro
ID : IG-20107
Organisme : Fondazione Cassa Risparmio Torino
ID : 2017.2954
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG-2017-20258
Références
Bioorg Med Chem Lett. 2011 Oct 1;21(19):5928-33
pubmed: 21856155
Cell. 2015 Jul 16;162(2):425-440
pubmed: 26186194
Oncogene. 2008 Nov 24;27(55):7047-54
pubmed: 19029944
Structure. 2003 Nov;11(11):1453-9
pubmed: 14604535
Nat Rev Cancer. 2010 Dec;10(12):858-70
pubmed: 21102636
J Neurosci. 2011 Aug 24;31(34):12094-103
pubmed: 21865452
Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14938-43
pubmed: 21873224
BMC Cancer. 2010 Nov 04;10:602
pubmed: 21050441
Cell Death Dis. 2018 Apr 19;9(4):438
pubmed: 29739921
PLoS One. 2013;8(1):e54931
pubmed: 23383002
J Neurosci. 2019 Jul 17;39(29):5634-5646
pubmed: 31092585
Nucleic Acids Res. 2015 Mar 11;43(5):2489-98
pubmed: 25712102
Eur J Cancer. 2014 Mar;50(5):1013-24
pubmed: 24456795
Exp Cell Res. 2018 Sep 1;370(1):174-188
pubmed: 29928866
N Engl J Med. 1999 Jun 24;340(25):1954-61
pubmed: 10379019
J Clin Oncol. 2009 Jan 10;27(2):298-303
pubmed: 19047290
Semin Cancer Biol. 2020 Feb;60:214-224
pubmed: 31386907
Clin Pharmacol Ther. 2018 Jun;103(6):1061-1073
pubmed: 28891208
Trends Cell Biol. 2004 Jan;14(1):36-44
pubmed: 14729179
Int J Cancer. 1989 Apr 15;43(4):665-71
pubmed: 2467885
Exp Ther Med. 2020 Feb;19(2):1112-1120
pubmed: 32010277
Front Mol Neurosci. 2017 Jun 30;10:212
pubmed: 28713243
Cancer Res. 2013 Jul 1;73(13):3852-64
pubmed: 23633489
Breast Cancer Res. 2010;12(3):R25
pubmed: 20459607
J Bone Miner Res. 2009 Sep;24(9):1537-43
pubmed: 19338451
Clin Cancer Res. 2017 Apr 1;23(7):1771-1784
pubmed: 27797972
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9623-8
pubmed: 27506785
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Neuron. 2009 Jan 15;61(1):85-100
pubmed: 19146815
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7434-9
pubmed: 23592719
Cell Signal. 2012 Feb;24(2):353-62
pubmed: 21893191
Pathol Res Pract. 2019 Jun;215(6):152382
pubmed: 30890278
Nat Commun. 2017 Mar 16;8:14797
pubmed: 28300085
Mol Med Rep. 2019 Oct;20(4):3140-3148
pubmed: 31432113
Am J Cancer Res. 2011;1(5):663-73
pubmed: 21994904
Am J Transl Res. 2015 Nov 15;7(11):2519-26
pubmed: 26807196
Neuron. 2017 Jun 21;94(6):1155-1172.e8
pubmed: 28641114
Sci Signal. 2010 Sep 14;3(139):re6
pubmed: 20841568
Exp Ther Med. 2019 Oct;18(4):2667-2674
pubmed: 31572515
J Proteome Res. 2006 Sep;5(9):2372-9
pubmed: 16944949
Oncogene. 2012 Feb 2;31(5):624-33
pubmed: 21725361
Cell Death Differ. 2020 Apr;27(4):1448
pubmed: 31488891
Sci Rep. 2017 Jul 13;7(1):5272
pubmed: 28706196
Exp Ther Med. 2019 Mar;17(3):2221-2229
pubmed: 30867707
EMBO J. 2007 Jun 20;26(12):2843-55
pubmed: 17525734
Dev Cell. 2007 Feb;12(2):221-34
pubmed: 17276340
Curr Opin Immunol. 2001 Jun;13(3):299-306
pubmed: 11406361
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
pubmed: 22700443
Expert Opin Ther Targets. 2014 Dec;18(12):1395-406
pubmed: 25189706
FEBS Lett. 2015 Jun 22;589(14):1577-87
pubmed: 25979173
Mol Neurobiol. 2017 Dec;54(10):8090-8109
pubmed: 27889896
Annu Rev Med. 2015;66:49-63
pubmed: 25386934
Nat Rev Cancer. 2004 Sep;4(9):688-94
pubmed: 15343275
Genetics. 2006 Jan;172(1):445-56
pubmed: 16204209
Oncotarget. 2017 May 8;8(36):60109-60122
pubmed: 28947957
Oncol Res. 2018 May 7;26(4):573-579
pubmed: 28550679
Mol Cell Proteomics. 2008 Nov;7(11):2123-37
pubmed: 18614564
Prog Biophys Mol Biol. 2008 Sep;98(1):85-106
pubmed: 18619997
Nat Commun. 2013;4:2136
pubmed: 23868368
Pathol Res Pract. 2019 Apr;215(4):738-747
pubmed: 30679084
Cytokine. 2017 Oct;98:42-50
pubmed: 28579221
Nat Rev Cancer. 2003 Mar;3(3):203-16
pubmed: 12612655
Oncol Res. 2019 Aug 8;27(8):879-887
pubmed: 30982489
FEBS Lett. 2015 Jan 30;589(3):407-13
pubmed: 25554419
Breast Cancer Res. 2011 Feb 02;13(1):R15
pubmed: 21288332
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
J Proteome Res. 2008 Jan;7(1):311-8
pubmed: 18034455
Sci Signal. 2015 Mar 10;8(367):re1
pubmed: 25759479
Am J Cancer Res. 2020 Dec 01;10(12):4308-4324
pubmed: 33415001
Sci Data. 2018 Mar 06;5:180031
pubmed: 29509190
Mol Biol Cell. 2004 Feb;15(2):787-800
pubmed: 14657239
Mol Cell. 2002 Oct;10(4):745-55
pubmed: 12419219
Tumour Biol. 2016 Jan;37(1):1151-7
pubmed: 26277787
J Neurochem. 2008 Oct;107(1):61-72
pubmed: 18662323
J Biol Chem. 2000 Jan 14;275(2):1191-200
pubmed: 10625663
Front Cell Dev Biol. 2019 Oct 15;7:222
pubmed: 31681758
Am J Cancer Res. 2013 Jun 20;3(3):290-301
pubmed: 23841028
J Neurosci. 2014 Jan 22;34(4):1542-53
pubmed: 24453341
Cancer Res Treat. 2019 Oct;51(4):1653-1665
pubmed: 31010277
Nature. 2017 May 25;545(7655):505-509
pubmed: 28514442
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Med Mol Morphol. 2013 Mar;46(1):41-8
pubmed: 23325552
Oncogene. 2010 Jun 24;29(25):3677-90
pubmed: 20453886
F1000Res. 2018 Sep 18;7:
pubmed: 30271576
Nat Rev Mol Cell Biol. 2015 Jan;16(1):18-29
pubmed: 25531225
J Clin Oncol. 2005 Apr 1;23(10):2280-99
pubmed: 15800319